Abeona Therapeutics (ABEO): Visibility Improves Multiple, Raising PT - Maxim

September 29, 2016 7:58 AM EDT
Get Alerts ABEO Hot Sheet
Price: $5.95 +0.85%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 31 | New: 25
Trade ABEO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of Abeona Therapeutics (NASDAQ: ABEO) but raised his price target to $14 from $8 on reduced risk driving the multiple higher.

The analyst sees the "risk" in the Abeona story being reduced one patient and one data point at a time, resulting in a rising valuation. Over the next 12 months, multiple data points across several gene therapy programs should drive Abeona's valuation higher, as happened for AveXis, bluebird (NASDAQ: BLUE), Kite (NASDAQ: KITE), and Juno (NASDAQ: JUNO). The analyst reduced the risk in his model to 80%, from 90%, which increased the price target to $14, from $8. More data = lower risk = higher valuation.

For an analyst ratings summary and ratings history on Abeona Therapeutics click here. For more ratings news on Abeona Therapeutics click here.

Shares of Abeona Therapeutics closed at $5.74 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Maxim Group

Add Your Comment